利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

67 条记录 (耗时 0.04 秒)

    METHODS AND COMPOSITIONS FOR MODULATING IL-17F/IL-17A BIOLOGICAL ACTIVITY
    1.
    发明申请
    METHODS AND COMPOSITIONS FOR MODULATING IL-17F/IL-17A BIOLOGICAL ACTIVITY 审中-公开

    公开(公告)号：US20080241130A1

    公开(公告)日：2008-10-02

    申请号：US12057778

    申请日：2008-03-28

    申请人： Jill F. Wright ,  Spencer C. Liang ,  Frances K. Bennett ,  Mary Collins ,  Beatriz M. Carreno

    发明人： Jill F. Wright ,  Spencer C. Liang ,  Frances K. Bennett ,  Mary Collins ,  Beatriz M. Carreno

    IPC分类号： A61K39/395 ,  G01N33/557 ,  A61K38/17 ,  A61P11/06

    CPC分类号： G01N33/6869 ,  G01N2333/54 ,  G01N2500/02

    摘要： The invention provides a novel mouse IL-17F/IL-17A, and further provides uses of such mouse IL-17F/IL-17A in the characterization of the IL-17F/IL-17A heterodimer. The present invention is also related to polynucleotides and polypeptides of the IL-17F/IL-17A signaling pathway, and targeting of the IL-17F/IL-17A signaling pathway in methods of treating IL-17F/IL-17A-associated disorders. The invention thus provides methods of using isolated IL-17F/IL-17A heterodimer, e.g., in a mouse model of airway inflammation, and specific or selective IL-17F/IL-17A modulators (e.g., signaling agonists or signaling antagonists (e.g., specific or selective antagonistic antibodies, specific or selective antagonistic small molecules, etc.)). The invention also provides methods of screening for compounds capable of modulating IL-17F/IL-17A biological activity, e.g., IL-17F/IL-17A signaling antagonists (e.g., using the mouse model of airway inflammation), as well as methods of identifying whether the IL-17F/IL-17A modulator is a specific IL-17F/IL-17A modulator. The invention is also directed to novel methods for diagnosing, prognosing, monitoring, preventing, and/or treating IL-17F/IL-17A-associated disorders, including, but not limited to, inflammatory disorders (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., airway inflammation, chronic obstructive pulmonary disease, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (e.g., ulcerative colitis, Crohn's disease). The present invention is further directed to novel therapeutics and therapeutic targets identified by methods of screening of the invention, and uses of such identified therapeutics in methods of treatment and prevention of IL-17F/IL-17A-associated disorders.

    INTERLEUKIN-17F ANTIBODIES AND OTHER IL-17F SIGNALING ANTAGONISTS AND USES THEREFOR
    7.
    发明申请
    INTERLEUKIN-17F ANTIBODIES AND OTHER IL-17F SIGNALING ANTAGONISTS AND USES THEREFOR 审中-公开
    白细胞介素-17F抗体及其他IL-17F信号拮抗剂及其用途

    公开(公告)号：US20110033451A1

    公开(公告)日：2011-02-10

    申请号：US12827199

    申请日：2010-06-30

    申请人： Beatriz M. Carreno ,  Mary Collins ,  Jill F. Wright ,  Neil M. Wolfman ,  Maya Arai ,  Kenneth Jacobs ,  Zhijian Lu ,  Yongjing Guo ,  Yongchang Qiu

    发明人： Beatriz M. Carreno ,  Mary Collins ,  Jill F. Wright ,  Neil M. Wolfman ,  Maya Arai ,  Kenneth Jacobs ,  Zhijian Lu ,  Yongjing Guo ,  Yongchang Qiu

    IPC分类号： A61K39/395 ,  A61K33/24 ,  A61K38/02 ,  A61K31/7088 ,  A61P11/06 ,  A61P29/00 ,  A61P19/02 ,  A61P17/06

    CPC分类号： C07K16/244 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/55527 ,  C07K14/54 ,  C07K14/7155 ,  C07K16/2866 ,  C07K2317/76 ,  C07K2319/30 ,  C12N15/1138 ,  G01N33/6869

    摘要： The present invention provides isolated and purified polynucleotides and polypeptides related to the IL-17F signaling pathway. The invention also provides antibodies to IL-17F homodimers and IL-17A/IL-17F heterodimers, and methods of isolating and purifying members of the IL-17 family, including IL-17A/IL-17F heterodimers, from a natural source. The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating and/or preventing disorders related to IL-17F signaling, i.e., IL-17F-associated disorders, including, but not limited to, inflammatory disorders, such as autoimmune diseases (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., COPD, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (IBDs, e.g., ulcerative colitis, Crohn's disease). The present invention is further directed to novel therapeutics and therapeutic targets, and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of disorders related to IL-17F signaling.

    摘要翻译： 本发明提供与IL-17F信号通路相关的分离和纯化的多核苷酸和多肽。 本发明还提供了对IL-17F同源二聚体和IL-17A / IL-17F异二聚体的抗体，以及从天然来源分离和纯化IL-17家族成员（包括IL-17A / IL-17F异源二聚体）的方法。 本发明还涉及用于诊断，预后，监测与IL-17F信号传导相关的疾病的进展和/或预防的新方法，即IL-17F相关疾病，包括但不限于炎性 诸如自身免疫性疾病（例如关节炎（包括类风湿性关节炎），牛皮癣，系统性红斑狼疮和多发性硬化症），呼吸系统疾病（例如COPD，囊性纤维化，哮喘，过敏），移植排斥（包括实体器官移植排斥 ）和炎症性肠病或疾病（IBD，例如溃疡性结肠炎，克罗恩病）。 本发明还涉及新的治疗和治疗靶标，以及筛选和评估用于干预（治疗）的试验化合物和预防与IL-17F信号传导相关的紊乱的方法。